Insights

  • Home
  • Insights
  • Inherent Obviousness: Available IPR Rationale With a High Standard, PTAB Litigation

Share

Inherent Obviousness: Available IPR Rationale With a High Standard, <i>PTAB Litigation</i>

Inherent Obviousness: Available IPR Rationale With a High Standard, PTAB Litigation

December 08, 2017 Blog

Visit the Jones Day PTAB Litigation Blog.

On November 28, 2017, the PTAB issued a final written decision upholding the patentability of U.S. Patent No. 6,667,061 (IPR2016-01096). The ’061 patent is owned by Alkermes Pharma Ireland, Ltd. and Alkermes Controlled Therapeutics, Inc. ("Alkermes"), and is listed in the Orange Book in connection with formulations of risperidone (Janssen Pharmaceuticals, Inc.) and naltrexone (Alkermes, Inc.), as well as several formulations by AstraZeneca AB (exenatide, synthetic exenatide, and dapagliflozin propanediol). Luye Pharma Group Ltd. ("Luye") challenged several of the claims on various obviousness grounds, including assertions of the inherent properties of prior art formulations. Our previous report on the PTAB’s decision to institute this IPR can be found here.

Read the full article at ptablitigationblog.com.

Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
You May Also Be Interested In

May 23, 2025 Commentary

Revolutionizing EU Design Protection: Key Changes Under the New Designs and Models Regulation

May 22, 2025 Blog

Estoppel Trumps Substance: ITC Bars Respondent’s Invalidity Grounds Raised in IPR, PTAB Litigation Blog

May 22, 2025 Commentary

U.S. Copyright Office Issues Guidance on Generative AI Training

May 16, 2025 Blog

Trial Date Drives PTAB’s Denial of IPR Institution, PTAB Litigation Blog

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.